On the other hand, the linkage between APOE4 and late-onset AD is one of the major foundations of the preclinical/prodromal hypothesis, which poses that any difference in cognitive performance that emerges between healthy APOE4 carriers and non-carriers would be secondary to the ɛ4 allele’s capability to increase the risk of AD [7]. This evidence concerns the gene APOE and Alzheimer disease.